共 50 条
- [31] Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ studyFRONTIERS IN NEUROLOGY, 2024, 15Crawford, Thomas O.Day, John W.De Vivo, Darryl C.Krueger, Jena M.Mercuri, EugenioNascimento, AndresPasternak, AmyMazzone, Elena StacyDuong, TinaSong, GuochenMarantz, Jing L.Baver, ScottYu, DongziLiu, LanDarras, Basil T.
- [32] MRI Outcomes in Patients Treated with Daclizumab in the EXTEND Open-Label Extension Study: Interim Report at Week 48NEUROLOGY, 2017, 88Cohan, StanleyArnold, Douglas L.Kappos, LudwigMokliatchouk, OksanaGreenberg, Steven J.Fam, Sami
- [33] Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II)EUROINTERVENTION, 2018, 14 (09) : E1057 - E1066Katagiri, YukiOnuma, YoshinobuAsano, TakuChichareon, PlyCollet, CarlosMiyazaki, YosukePiek, Jan J.Wykrzykowska, Joanna J.Abizaid, AlexandreOrmiston, John A.Chevalier, BernardSerruys, Patrick W.
- [34] Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) studyBMC PSYCHIATRY, 2012, 12Hong, JihyungNovick, DiegoBrugnoli, RobertoKaragianis, JamieDossenbach, MartinHaro, Josep Maria
- [35] Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) studyBMC Psychiatry, 12Jihyung HongDiego NovickRoberto BrugnoliJamie KaragianisMartin DossenbachJosep Maria Haro
- [36] Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME StudyOPHTHALMIC RESEARCH, 2019, 62 (02) : 101 - 110Massin, PascaleCreuzot-Garcher, CatherineKodjikian, LaurentGirmens, Jean-FrancoisDelcourt, CecileFajnkuchen, FrankGlacet-Bernard, AgnesGuillausseau, Pierre-JeanPonthieux, AnneBlin, PatrickGrelaud, Angela
- [37] ABSORB FIRST: An interim report on baseline characteristics and acute performance on the first 1,200 patients from a prospective, multi-center, global registryJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (11) : B179 - B179Eeckhout, EricSeth, AshokMao, Vivian W.Gao, YuanCheong, Wai-FungStaehr, PeterNaber, Christoph
- [38] 36-month cost-utility analysis of antipsychotic treatments in patients with schizophrenia in the pan-European soho (schizophrenia outpatient health outcomes) studyVALUE IN HEALTH, 2007, 10 (03) : A78 - A79Windmeijer, F.Brown, J.Novick, D.Hong, J.Knapp, M.Kontodimas, S.Ratcliffe, M.
- [39] Comparison of treatment outcomes in severe personality disorder patients with or without substance use disorders: a 36-month prospective pragmatic follow-up studyNEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 1477 - 1487Lana, FernandoSanchez-Gil, CarmenAdroher, Nuria D.Perez, VictorFeixas, GuillemMarti-Bonany, JosepTorrens, Marta
- [40] One-year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds: A Pooled Analysis From the ABSORB Cohort B and the ABSORB EXTEND Trials.JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : B12 - B13Muramatsu, TakashiOnuma, YoshinobuVan Geuns, Robert J.Chevalier, BernardPatel, Tejas M.Seth, AshokDiletti, RobertoGarcia-Garcia, Hector M.Dorange, CecileVeldhof, SusanCheong, Wai-FungWhitbourn, Robert J.Bartorelli, Antonio L.Abizaid, AlexandreSerruys, Patrick W.